Tags

Type your tag names separated by a space and hit enter

Revisiting CB1 receptor as drug target in human melanoma.
Pathol Oncol Res. 2012 Oct; 18(4):857-66.PO

Abstract

Previous studies have indicated the antitumoral effect of human melanocytes, human melanoma cell lines expressing CB1 receptor (CB1), and of the peritumoral administration of endocannabinoids. In the present study, we systematically screened several human melanoma cell lines for the expression of CNR1 and demonstrated transcription of the authentic gene. The product of CNR1, the CB1 protein, was found localized to the cell membrane as well as to the cytoskeleton. Further, the studied human melanoma cell lines expressed functional CB1 since physiological and synthetic ligands, anandamide (AEA), Met-F-AEA, ACEA and AM251 showed a wide range of biological effects in vitro, for example anti-proliferative, proapoptotic and anti-migratory. More importantly, our studies revealed that systemic administration of a stable CB1 agonist, ACEA, into SCID mice specifically inhibited liver colonization of human melanoma cells. Since therapeutic options for melanoma patients are still very limited, the endocannabinoid-CB1 receptor system may offer a novel target.

Authors+Show Affiliations

2nd Department of Pathology, Semmelweis University, Üllői út 93., Budapest, 1091, Hungary. steveken12@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22447182

Citation

Kenessey, István, et al. "Revisiting CB1 Receptor as Drug Target in Human Melanoma." Pathology Oncology Research : POR, vol. 18, no. 4, 2012, pp. 857-66.
Kenessey I, Bánki B, Márk A, et al. Revisiting CB1 receptor as drug target in human melanoma. Pathol Oncol Res. 2012;18(4):857-66.
Kenessey, I., Bánki, B., Márk, A., Varga, N., Tóvári, J., Ladányi, A., Rásó, E., & Tímár, J. (2012). Revisiting CB1 receptor as drug target in human melanoma. Pathology Oncology Research : POR, 18(4), 857-66.
Kenessey I, et al. Revisiting CB1 Receptor as Drug Target in Human Melanoma. Pathol Oncol Res. 2012;18(4):857-66. PubMed PMID: 22447182.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Revisiting CB1 receptor as drug target in human melanoma. AU - Kenessey,István, AU - Bánki,Balázs, AU - Márk,Agnes, AU - Varga,Norbert, AU - Tóvári,József, AU - Ladányi,Andrea, AU - Rásó,Erzsébet, AU - Tímár,József, Y1 - 2012/03/24/ PY - 2011/06/30/received PY - 2012/03/01/accepted PY - 2012/3/27/entrez PY - 2012/3/27/pubmed PY - 2013/4/26/medline SP - 857 EP - 66 JF - Pathology oncology research : POR JO - Pathol Oncol Res VL - 18 IS - 4 N2 - Previous studies have indicated the antitumoral effect of human melanocytes, human melanoma cell lines expressing CB1 receptor (CB1), and of the peritumoral administration of endocannabinoids. In the present study, we systematically screened several human melanoma cell lines for the expression of CNR1 and demonstrated transcription of the authentic gene. The product of CNR1, the CB1 protein, was found localized to the cell membrane as well as to the cytoskeleton. Further, the studied human melanoma cell lines expressed functional CB1 since physiological and synthetic ligands, anandamide (AEA), Met-F-AEA, ACEA and AM251 showed a wide range of biological effects in vitro, for example anti-proliferative, proapoptotic and anti-migratory. More importantly, our studies revealed that systemic administration of a stable CB1 agonist, ACEA, into SCID mice specifically inhibited liver colonization of human melanoma cells. Since therapeutic options for melanoma patients are still very limited, the endocannabinoid-CB1 receptor system may offer a novel target. SN - 1532-2807 UR - https://www.unboundmedicine.com/medline/citation/22447182/Revisiting_CB1_receptor_as_drug_target_in_human_melanoma_ L2 - http://por.hu/2012/18/4/0857/0857a.pdf DB - PRIME DP - Unbound Medicine ER -